Lexaria Bioscience vs Seres Therapeutics
Seres Therapeutics reported revenue of $1 million in fiscal 2025, about the same as Lexaria Bioscience's $1 million in fiscal 2025. Lexaria Bioscience had an operating margin of -1683.0%, against -11910.1% at Seres Therapeutics. Free cash flow was −$10 million at Lexaria Bioscience and $1 million at Seres Therapeutics. Their fiscal years end in different months (August 31 and December 31), so the periods don't line up exactly.
Side by side
| Lexaria Bioscience | Seres Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Aug 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1M | $1M |
| Revenue growth | 52.0% | — |
| Revenue growth a year, last 5 years | 18.5% | −52.5% |
| Gross margin | 99.6% | — |
| Operating margin | −1,683.0% | −11,910.1% |
| Net margin | −1,686.0% | 721.9% |
| Free cash flow | −$10M | $1M |
| Free cash flow margin | −1,483.9% | 109.6% |
| Return on capital | −929.6% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 45.3% | 14.2% |
| Last close | $4.49 | $1.33 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $10,043 |
| Piotroski F-score | 3 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Lexaria BioscienceSeres Therapeutics
Operating margin
Percent of revenue
Lexaria BioscienceSeres Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lexaria BioscienceSeres Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lexaria Bioscience and Seres Therapeutics pages.